MedDataX Logo

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

NCT ID: NCT00035009

Last Updated: 2017-04-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

468 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-09-20

Study Completion Date

2004-03-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

NCT00035295

Major Depressive Disorder
COMPLETED PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

NCT00048607

Major Depressive Disorder
COMPLETED PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

NCT00034983

Major Depressive Disorder
COMPLETED PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

NCT00034944

Major Depressive Disorder
COMPLETED PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

NCT00042029

Major Depressive Disorder
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The duration of treatment is 8 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0869, aprepitant

Intervention Type DRUG

Comparator: paroxetine HCL

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Major Depressive Disorder
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

References

Explore related publications, articles, or registry entries linked to this study.

Liu KS, Snavely DB, Ball WA, Lines CR, Reines SA, Potter WZ. Is bigger better for depression trials? J Psychiatr Res. 2008 Jul;42(8):622-30. doi: 10.1016/j.jpsychires.2007.07.003. Epub 2007 Sep 7.

Reference Type BACKGROUND
PMID: 17825841 (View on PubMed)

Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006 Feb 1;59(3):216-23. doi: 10.1016/j.biopsych.2005.07.013. Epub 2005 Oct 24.

Reference Type RESULT
PMID: 16248986 (View on PubMed)

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: CSR Synopsis Links

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Formally-1A407

Identifier Type: -

Identifier Source: secondary_id

MK0869-059

Identifier Type: -

Identifier Source: secondary_id

2006_402

Identifier Type: -

Identifier Source: secondary_id

0869-059

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)
NCT00035282 COMPLETED PHASE3
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
NCT00035048 COMPLETED PHASE3
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
NCT00048594 COMPLETED PHASE3
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
NCT04937829 COMPLETED PHASE1
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
NCT00610649 COMPLETED PHASE2
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
NCT00733980 COMPLETED PHASE2
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
NCT01741142 TERMINATED PHASE2
Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder
NCT01380704 COMPLETED PHASE1
Clinical Study to Test a New Drug to Treat Major Depression
NCT00976560 COMPLETED PHASE2
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
NCT06785012 RECRUITING PHASE2
This is a Study to Determine the Antidepressant Effects of AZD6765
NCT00986479 COMPLETED PHASE2
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111539 TERMINATED PHASE3
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
NCT05593029 COMPLETED PHASE2
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
NCT01098240 TERMINATED PHASE2
Safety and Efficacy Study in Patients With Major Depressive Disorder
NCT00896363 COMPLETED PHASE2
A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder
NCT02724735 UNKNOWN
Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder
NCT00593879 COMPLETED PHASE2
Treatment of Depression in Adults
NCT00073697 COMPLETED PHASE4
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
NCT00969709 COMPLETED PHASE3
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
NCT04663321 TERMINATED PHASE2
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401 RECRUITING PHASE3
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
NCT02749721 COMPLETED PHASE4
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111552 TERMINATED PHASE3
A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression
NCT01814085 COMPLETED PHASE4
A Study to Test Different Doses of BI 1569912 in People With Depression
NCT06558344 COMPLETED PHASE2